(Q34519277)

2 August 2017

1 reference

title

A review of pramipexole and its clinical utility in Parkinson's disease (English)

1 reference

2 August 2017

1 reference

Kevin M Biglan

1

1 reference

2 August 2017

Robert G Holloway

series ordinal

2

1 reference

2 August 2017

language of work or name

English

0 references

publication date

1 February 2002

1 reference

Expert Opinion on Pharmacotherapy

2 August 2017

published in

1 reference

2 August 2017

volume

3

1 reference

2 August 2017

issue

2

1 reference

2 August 2017

page(s)

197-210

1 reference

Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990.

2 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Inhibition of dopamine neuron firing by pramipexole, a dopamine D3 receptor-preferring agonist: comparison to other dopamine receptor agonists.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Biochemical and pharmacological studies on pramipexole, a potent and selective dopamine D2 receptor agonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Efficacy of pramipexole, a new dopamine receptor agonist, to relieve the parkinsonian-like muscle rigidity in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Pramipexole, a dopamine D2 autoreceptor agonist, decreases the extracellular concentration of dopamine in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Behavioral and neurochemical data suggest functional differences between dopamine D2 and D3 receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

A comparison of dopamine agonists and catechol-O-methyltransferase inhibitors in Parkinson's disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

A double-blind randomized crossover trial of bromocriptine and placebo in restless legs syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Dopamine autoreceptor agonists in the treatment of schizophrenic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Neuroprotective effects of the dopamine D2/D3 agonist pramipexole against postischemic or methamphetamine-induced degeneration of nigrostriatal neurons.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Partial purification of a pramipexole-induced trophic activity directed at dopamine neurons in ventral mesencephalic cultures

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Non-ergot dopamine agonist-induced sleep attacks.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

A study of excessive daytime sleepiness and its clinical significance in three groups of Parkinson's disease patients taking pramipexole, cabergoline and levodopa mono and combination therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Pramipexole-induced somnolence and episodes of daytime sleep

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Clinical Characteristics of Pramipexole-Induced Peripheral Edema

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

Pramipexole as adjunct to haloperidol in schizophrenia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.3.2.197

21 January 2018

Identifiers

DOI

10.1517/14656566.3.2.197

1 reference

2 August 2017

1 reference